Calcineurin inhibitors in bronchiolitis obliterans syndrome following stem cell transplantation

European Respiratory Journal

Volumn 43, Issue 1, 2014, Pages 221-232

  Hostettler, Katrin E ^a   Halter, Jörg P ^a   Gerull, Sabine ^a   Lardinois, Didier ^a   Savic, Spasenija ^b   Roth, Michael ^a   Tamm, Michael ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BRONCHIOLITIS; BRONCHIOLITIS OBLITERANS; CELL PROLIFERATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LUNG BIOPSY; LUNG FUNCTION TEST; LYMPHOCYTIC BRONCHIOLITIS; MALE; MYOFIBROBLAST; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; VIDEO ASSISTED THORACOSCOPIC SURGERY;

ADULT; BRONCHIOLITIS OBLITERANS; CALCINEURIN; CELL PROLIFERATION; CELLS, CULTURED; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; MALE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYOFIBROBLASTS; SIROLIMUS; TACROLIMUS;

EID: 84891957197     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00199312     Document Type: Review

References (62)

1. Ljungman P, Bregni M, Brune M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219-234.
2. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813-1826.
3. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956.
4. Chien JW, Martin PJ, Flowers ME, et al. Implications of early airflow decline after myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 33: 759-764.
5. Philit F, Wiesendanger T, Archimbaud E, et al. Post-transplant obstructive lung disease (''bronchiolitis obliterans''): A clinical comparative study of bone marrow and lung transplant patients. Eur Respir J 1995; 8: 551-558.
6. Hildebrandt GC, Fazekas T, Lawitschka A, et al. Diagnosis and treatment of pulmonary chronic GVHD: Report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant 2011; 46: 1283-1295.
7. Williams KM, Chien JW, Gladwin MT, et al. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009; 302: 306-314.
8. Chien JW, Duncan S, Williams KM, et al. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation - an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16: Suppl. 1, S106-S114.
9. Duncker C, Dohr D, Harsdorf S, et al. Non-infectious lung complications are closely associated with chronic graftversus- host disease: A single center study of incidence, risk factors and outcome. Bone Marrow Transplant 2000; 25: 1263-1268.
10. Yoshihara S, Yanik G, Cooke KR, et al. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 749-759.
11. Yousem SA. The histological spectrum of pulmonary graft-versus-host disease in bone marrow transplant recipients. Hum Pathol 1995; 26: 668-675.
12. Marras TK, Chan CK, Lipton JH, et al. Long-term pulmonary function abnormalities and survival after allogeneic marrow transplantation. Bone Marrow Transplant 2004; 33: 509-517.
13. Clark JG, Crawford SW, Madtes DK, et al. Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. Ann Intern Med 1989; 111: 368-376.
14. Snell GI, Esmore DS, Williams TJ. Cytolytic therapy for the bronchiolitis obliterans syndrome complicating lung transplantation. Chest 1996; 109: 874-878.
15. Cairn J, Yek T, Banner NR, et al. Time-related changes in pulmonary function after conversion to tacrolimus in bronchiolitis obliterans syndrome. J Heart Lung Transplant 2003; 22: 50-57.
16. Dudek AZ, Mahaseth H, DeFor TE, et al. Bronchiolitis obliterans in chronic graft-versus-host disease: Analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003; 9: 657-666.
17. Sakaida E, Nakaseko C, Harima A, et al. Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versusleukemia effect. Blood 2003; 102: 4236-4242.
18. Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004; 170: 22-48.
19. Hanssen L, Frye BC, Ostendorf T, et al. Y-box binding protein-1 mediates profibrotic effects of calcineurin inhibitors in the kidney. J Immunol 2011; 187: 298-308.
20. Ninova D, Covarrubias M, Rea DJ, et al. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: Differential intragraft expression of transforming growth factor-b1 and a-smooth muscle actin. Transplantation 2004; 78: 338-344.
21. Shihab FS, Andoh TF, Tanner AM, et al. Sodium depletion enhances fibrosis and the expression of TGF-b1 and matrix proteins in experimental chronic cyclosporine nephropathy. Am J Kidney Dis 1997; 30: 71-81.
22. Sobral LM, Aseredo F, Agostini M, et al. Molecular events associated with ciclosporin A-induced gingival overgrowth are attenuated by Smad7 overexpression in fibroblasts. J Periodontal Res 2012; 47: 149-158.
23. Hunt J, Cheng A, Hoyles A, et al. Cyclosporin A has direct effects on adult neural precursor cells. J Neurosci 2010; 30: 2888-2896.
24. Holbro A, Lehmann T, Girsberger S, et al. Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19: 973-980.
25. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, Official Statement of the European Respiratory Society. Eur Respir J 1993; 6: Suppl. 16, 5-40.
26. Tamm M, Roth M, Malouf M, et al. Primary fibroblast cell cultures from transbronchial biopsies of lung transplant recipients. Transplantation 2001; 71: 337-339.
27. Hostettler KE, Roth M, Burgess JK, et al. Cyclosporine A mediates fibroproliferation through epithelial cells. Transplantation 2004; 77: 1886-1893.
28. Santo Tomas LH, Loberiza FR Jr, Klein JP, et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest 2005; 128: 153-161.
29. Beschorner WE, Saral R, Hutchins GM, et al. Lymphocytic bronchitis associated with graft-versus-host disease in recipients of bone-marrow transplants. N Engl J Med 1978; 299: 1030-1036.
30. Boehler A, Chamberlain D, Kesten S, et al. Lymphocytic airway infiltration as a precursor to fibrous obliteration in a rat model of bronchiolitis obliterans. Transplantation 1997; 64: 311-317.
31. Nakamoto-Matsubara R, Nishikii H, Yamada K, et al. Early pathologic findings of bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: A proposal from a case. Case Report Hematol 2012; 2012: 957612.
32. Briffa N, Morris RE. New immunosuppressive regimens in lung transplantation. Eur Respir J 1997; 10: 2630-2637.
33. Aisa Y, Mori T, Nakazato T, et al. Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation. Transplantation 2005; 80: 1046-1050.
34. Mihatsch MJ, Kyo M, Morozumi K, et al. The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol 1998; 49: 356-363.
35. Lensmeyer GL, Wiebe DA, Carlson IH, et al. Concentrations of cyclosporin A and its metabolites in human tissues postmortem. J Anal Toxicol 1991; 15: 110-115.
36. Iacono AT, Corcoran TE, Griffith BP, et al. Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans. Eur Respir J 2004; 23: 384-390.
37. Hachem RR, Yusen RD, Chakinala MM, et al. A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation. J Heart Lung Transplant 2007; 26: 1012-1018.
38. Behar-Cohen FF, Gauthier S, El Aouni A, et al. Methylprednisolone concentrations in the vitreous and the serum after pulse therapy. Retina 2001; 21: 48-53.
39. Azzola A, Havryk A, Chhajed P, et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004; 77: 275-280.
40. Stewart AG, Fernandes D, Tomlinson PR. The effect of glucocorticoids on proliferation of human cultured airway smooth muscle. Br J Pharmacol 1995; 116: 3219-3226.
41. Ratjen F, Rjabko O, Kremens B. High-dose corticosteroid therapy for bronchiolitis obliterans after bone marrow transplantation in children. Bone Marrow Transplant 2005; 36: 135-138.
42. Ross DJ, Marchevsky A, Kramer M, et al. ''Refractoriness'' of airflow obstruction associated with isolated lymphocytic bronchiolitis/bronchitis in pulmonary allografts. J Heart Lung Transplant 1997; 16: 832-838.
43. Heinz C, Hudde T, Heise K, et al. Antiproliferative effect of mycophenolate mofetil on cultured human Tenon fibroblasts. Graefes Arch Clin Exp Ophthalmol 2002; 240: 408-414.
44. Badid C, Vincent M, McGregor B, et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 2000; 58: 51-61.
45. Tredger JM, Brown NW, Adams J, et al. Monitoring mycophenolate in liver transplant recipients: Toward a therapeutic range. Liver Transpl 2004; 10: 492-502.
46. McNeil K, Glanville AR, Wahlers TK, et al. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation 2006; 81: 998-1003.
47. Groetzner J, Wittwer T, Kaczmarek I, et al. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation 2006; 81: 355-360.
48. Speich R, Schneider S, Hofer M, et al. Mycophenolate mofetil reduces alveolar inflammation, acute rejection and graft loss due to bronchiolitis obliterans syndrome after lung transplantation. Pulm Pharmacol Ther 2010; 23: 445-449.
49. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36-42.
50. Bohler T, Waiser J, Budde K, et al. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. Transplant Proc 1998; 30: 2195-2197.
51. Snell GI, Valentine VG, Vitulo P, et al. Everolimus versus azathioprine in maintenance lung transplant recipients: An international, randomized, double-blind clinical trial. Am J Transplant 2006; 6: 169-177.
52. Pham PT, Pham PC, Danovitch GM, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004; 77: 1215-1220.
53. Vandewiele B, Vandecasteele SJ, Vanwalleghem L, et al. Diffuse alveolar hemorrhage induced by everolimus. Chest 2010; 137: 456-459.
54. Champion L, Stern M, Israel-Biet D, et al. Brief communication: Sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 2006; 144: 505-509.
55. Platzbecker U, von Bonin M, Goekkurt E, et al. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: Results of the EVTAC trial. Biol Blood Marrow Transplant 2009; 15: 101-108.
56. Vos R, Vanaudenaerde BM, Verleden SE, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 2011; 37: 164-172.
57. Martin PJ, Storer BE, Rowley SD, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graftversus- host disease. Blood 2009; 113: 5074-5082.
58. Verleden GM, Vanaudenaerde BM, Dupont LJ, et al. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006; 174: 566-570.
59. Verleden GM, Verleden SE, Vos R, et al. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A pilot study. Transpl Int 2011; 24: 651-656.
60. Norman BC, Jacobsohn DA, Williams KM, et al. Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: A case series of eight patients. Bone Marrow Transplant 2011; 46: 1369-1373.
61. Lam DC, Lam B, Wong MK, et al. Effects of azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT - a randomized double-blinded placebo-controlled study. Bone Marrow Transplant 2011; 46: 1551-1556.
62. Or R, Gesundheit B, Resnick I, et al. Sparing effect by montelukast treatment for chronic graft versus host disease: A pilot study. Transplantation 2007; 83: 577-581.